The glucagon-like peptide-1 receptor (GLP1R) is a G protein-coupled receptor (GPCR) found on beta cells of the pancreas and on neurons of the brain. It is involved in the control of blood sugar level by enhancing insulin secretion.

Healthcare providers prescribe GLP-1 agonists for two conditions: Type 2 diabetes and obesity. GLP-1 agonists for Type 2 diabetes. The FDA approves the use of GLP-1 agonists to help manage Type 2 diabetes (T2D). This is because GlP-1 agonists help lower blood sugar levels.

2024年9月18日 · The glucagon-like peptide-1 (GLP-1) receptor, known as GLP-1R, is a vital component of the G protein-coupled receptor (GPCR) family and is found primarily on the surfaces of various cell...

2024年2月29日 · GLP-1 agonists (also known as GLP-1 receptor agonists, incretin mimetics, or GLP-1 analogs) represent a class of medications used to treat T2DM and, in some cases, obesity. Examples of drugs in this class include Exenatide, Liraglutide, Dulaglutide, and Semaglutide.

GLP-1 agonists work by activating the GLP-1 receptor. They slow gastric emptying, inhibit the release of glucagon, and stimulate insulin production, therefore reducing hyperglycemia in people with type 2 diabetes. They also reduce food intake and therefore body weight, making them an effective treatment for obesity. [2]

2023年10月9日 · The glucagon-like peptide-1 receptor (GLP-1R) is a validated target for the treatment of diabetes and obesity, but drugs that target this receptor are a frequent cause of adverse events.

This review will encompass the synthesis, secretion, and metabolism of GLP-1, the structure and expression of the GLP-1r, the intracellular signaling initiated by GLP-1r stimulation, and GLP-1 changes after bariatric surgery.

These multiple effects have generated a great deal of interest in the discovery of long-lasting agonists of the GLP-1 receptor (GLP-1R) in order to treat type 2 diabetes. This review article summarizes the literature regarding the discovery of GLP-1 and its physiological functions.

GLP-1 acts through the GLP-1 receptor (GLP-1R) expressed on islet β cells and δ cells to control insulin and somatostatin (SMS) secretion, respectively. SMS in turn inhibits glucagon secretion from islet α cells via the somatostatin-2 receptor (SSTR2).

2024年12月2日 · What is GLP-1R? Glucagon-like peptide-1 receptors (GLP-1Rs) belong to the large family of G protein-coupled receptors whose activation triggers a cascade of intracellular events through associated G proteins.

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are attractive options for the treatment of type 2 diabetes (T2D) because they effectively lower A1C and weight while having a low risk of hypoglycemia. Some also have documented cardiovascular benefit.

The glucagon-like peptide-1 receptor (GLP-1R) is a significant therapeutic target for small molecule drug discovery given the therapeutic impact of peptide agonists in the diabetes sphere.

2020年11月5日 · The glucagon-like peptide-1 receptor (GLP-1R) is a class B1 GPCR that is the target of multiple clinically approved peptide drugs for the treatment of type 2 diabetes, with select drugs also approved for obesity (Brown et al., 2018; Nauck and Meier, 2019). These peptides have been engineered to enhance pharmacokinetic profiles over the rapidly ...

2024年12月25日 · GLP1R (Glucagon Like Peptide 1 Receptor) is a Protein Coding gene. Diseases associated with GLP1R include Insulinoma and Hyperglycemia. Among its related pathways are Integration of energy metabolism and GPCR downstream signalling.

2025年1月20日 · Glucagon-like peptide 1 receptor agonists (GLP-1RAs) are increasingly being used to treat diabetes and obesity. However, their effectiveness and risks have not yet been systematically evaluated in a comprehensive set of possible health outcomes. Here, we used the US Department of Veterans Affairs databases to build a cohort of people with ...

2018年12月13日 · Glucagon-like peptide 1 (GLP-1) is likely best known by many readers of Diabetes because of the role it plays in insulin secretion. Indeed, GLP-1 receptor (GLP-1R) agonists have become important tools for glycemic control in the treatment of type 2 diabetes.

In recent years, glucagon-like peptide 1 receptor agonists (GLP-1RAs) have become central in the treatment of type 2 diabetes (T2D). In addition to their glucose-lowering properties with low risk of hypoglycaemia, GLP-1RAs reduce body weight and ...

2024年10月7日 · GLP-1 receptor agonists are a non-insulin type 2 diabetes medication. GLP-1 agonists help to lower blood sugar and aid in weight loss. Drugs in this class include Byetta (exenatide), Victoza (liraglutide), Trulicity (dulaglutide), and Ozempic (semaglutide) among others.

5 天之前 · Kidney stones are among the possible risks of GLP-1 use that were not previously known. Glucagon-like peptide 1 receptor agonists (GLP-1RAs) may have a wider range of benefits and risks than what ...

2024年12月2日 · Clinical demand for agents from the glucagon-like peptide-1 receptor agonist (GLP-1 RA) and dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 RA (dual GIP/GLP-1 RA) classes has increased dramatically in recent years ().These medications are recommended by the American Diabetes Association (ADA) for use in people with type 2 …

2024年6月4日 · Glucagon-like peptide-1 receptor (GLP-1R) is a key regulator of glucose metabolism known to be expressed by pancreatic β cells. We herein investigated the role of GLP-1R on T lymphocytes during immune response.

FDA approved the first generic referencing Victoza (liraglutide injection) 18 mg/3 mL, a glucagon-like peptide-1 (GLP-1) receptor agonist indicated to improve glycemic control in adults and ...

Glucagon-like peptide-1 receptor (GLP-1R) plays an important role in glucose homeostasis and treatment of type 2 diabetes. Here authors report the peptide-free crystal structure of human GLP-1R in an inactive state which reveals a unique closed conformation of the extracellular domain.

1 天前 · Advice for healthcare professionals: glucagon-like peptide-1 (GLP-1) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists, such as the dual agonist tirzepatide, are ...

1 天前 · The hazard ratio (HR) of thyroid cancer in the GLP-1RA group was 1.24 as compared to those prescribed non-GLP-1RA medications. Among patients initiating GLP-1RA use during the initial year of ...

2025年1月15日 · The GLP-1 receptor (GLP-1R) is expressed in the pancreas, lung, smooth muscle, specific immune cells, and across the central and peripheral nervous systems. PHYSIOLOGICAL ROLE: GLP-1 acts on the central and peripheral nervous systems to suppress feeding, and on the islets to stimulate insulin and suppress glucagon secretion.

Metabolic dysfunction-associated steatotic liver disease (MASLD) poses a major global health challenge. glucagon-like peptide-1 receptor agonists (GLP-1RAs) have shown potential therapeutic benefits for MASLD patients, including improvements in liver function, inflammation, and fibrosis. This study aims to systematically review and meta-analyze randomized controlled …